Fig. 2.

Depletion of Tregs during IL-2 cplx treatment leads to rapid graft rejection. (A) Mice were treated with IL-2 cplx-based tolerance protocol (cplx protocol) and grafted with BALB/c skin (n = 6; MST = 64 d); some mice were treated with anti-CD25 mab (day 25, indicated with dashed gray line) to deplete Tregs (cplx protocol + a-CD25: n = 5; MST = 29 d, P = 0.0029). (B and C) Peripheral blood was analyzed on day 30 to measure frequency of (B) FoxP3⁺ Tregs among CD4⁺ subset and (C) total CD4 T cells among leukocytes (naïve n = 2, cplx protocol n = 5, cplx protocol + a-CD25 n = 4; 2-tailed t test with unequal variances).